Purdue Pharma L.P.
Case Number:
7:19-bk-23649
Court:
Nature of Suit:
Firms
- Phillips Lytle
- Brown & Connery
- Ice Miller
- Foley & Lardner
- Skadden Arps
- Tarter Krinsky
- Teitelbaum Law Group
- Duane Morris
- Hagens Berman
- Simmons Hanly
- Motley Rice
- Debevoise & Plimpton
- Bielli & Klauder
- Godfrey & Kahn
- Himes Petrarca
- Manatt Phelps
- Wachtell Lipton
- Hurwitz Fine
- Morris Nichols
- Gilbert LLP
- BatesCarey
- Lowe Stein
- Arnold & Porter
- Archer & Greiner
- Katsky Korins
- Brown Rudnick
- Gage Spencer & Fleming
- Pashman Stein
- Hogan Lovells
- Katten Muchin
- Morrison & Foerster
- Doshi Legal Group
- Willkie Farr
- Buchalter LLP
- FBT Gibbons
- Terrell Hogan
- Goodwin Procter
- Davis Polk
- Pillsbury Winthrop
- ArentFox Schiff
- Crowell & Moring
- McDermott Will & Schulte
- Gertz & Rosen
- Consovoy McCarthy
- Porteous Hainkel
- Rothstein Mandell
- Caplin & Drysdale
- Jones Day
- Porter Hedges
- Kirkland & Ellis
- Bentley & Bruning
- ASK LLP
- Dentons
- Faegre Drinker
- Joseph Hage
- Doster Ullom
- Marino Tortorella
- White & Case
- Boies Schiller
- HSF Kramer
- Spangenberg Shibley
- Cuneo Gilbert
- MoloLamken
- Morgan Lewis
- Blitman & King
- WilmerHale
- Latham & Watkins
- Akin Gump
- McElroy Deutsch
- Jenner & Block
- Reed Smith
- Kobre & Kim
- O'Melveny & Myers
- Seyfarth Shaw
- Alston & Bird
- King & Spalding
- Troutman
- Stevens & Lee
- Mintz Levin
- WestLoop Law
- Miller Nash LLP
- Cronin Fried
- Loeb & Loeb
- Diamond McCarthy
- Slevin & Hart
- Plevin & Turner
- Schenck Price
- Bialson Bergen
- Martin S. Rapaport
- Akerman LLP
- Fox Swibel
- Lerner Arnold
- Burke Warren
- Shook Hardy
- Sherrard Roe
- Taft Stettinius
- Sahn Ward
- Cleary Gottlieb
- Simpson Thacher & Bartlett
- Napoli Shkolnik
- D. Miller & Associates
- McGrail & Bensinger
- Marcus & Shapira
- Quinn Emanuel
- Pachulski Stang
- UB Greensfelder
- Wilk Auslander
- Shafferman & Feldman
- Squire Patton
- Hughes Socol
- Robins Kaplan
- Blank Rome
- Keller Rohrback
- Ballard Spahr
- Keller Postman
- Webb Law Firm
- Kleinberg Kaplan
- Clifford Law Offices
- Barack Ferrazzano
- Stutzman Bromberg
- Levenfeld Pearlstein
- MacElree Harvey
- Klehr Harrison
- Pullman & Comley
- Mehri & Skalet
- Tate Law Group LLC
- Lowey Dannenberg
- Williams Mullen
- Waldrep Wall
- Barclay Damon
- Dechert LLP
- Ifrah Law
- Seward & Kissel
- Calfee Halter
- White Coleman & Associates
- Miller Shah
- Susman Godfrey
- O'Brien Belland
- Binder & Schwartz
- Carter Ledyard
- Shipman & Goodwin
- Henrichsen Law Group
- Haug Partners
- Hobbs Straus
- Mayer Brown
- Milbank LLP
Companies
- Teamsters Local 456
- Henry Schein Inc.
- Cencora Inc.
- Bristol-Myers Squibb Co.
- Hikma Pharmaceuticals PLC
- Giant Eagle Inc.
- McKesson Corp.
- BDO LLP
- Otis Worldwide Corp.
- Johnson & Johnson
- Liberty Mutual Insurance Group
- FTI Consulting Inc.
- Kodiak Area Native Association
- Ranbaxy
- PRA Health Sciences Inc.
- Ascent Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Aleutian Pribilof Islands Association Inc.
- KVK Tech Inc.
- Collegium Pharmaceutical Inc.
- Noramco Inc.
- Endo International PLC
- Impax Laboratories, Inc.
- Omnicare Inc.
- Bausch Health Cos. Inc.
- Province LLC
- Sandoz International GmbH
- Avrio Health LP
- Nardello & Co. LLC
- DuPont de Nemours Inc.
- Hain Capital Group LLC
- United Parcel Service Inc.
- Express Scripts Holding Co.
- CVS Health Corp.
- Ironshore Inc.
- Amneal Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Loblaw Cos.
- Tucson Medical Center
- TR Capital Management LLC
- Viatris Inc.
- The Cigna Group
- Alaska Native Tribal Health Consortium
- Anda Inc.
- Walmart Inc.
- AXA XL Ltd.
- Allergan PLC
- BDO USA LLP
- Rubris Inc.
- AlixPartners LLP
- Purdue Pharma LP
- United Food & Commercial Workers International Union
- ASM Capital LP
- SAP AG
- Apria Healthcare Group
- Cardinal Health Inc.
- Arcadia Consumer Healthcare
- International Union Of Operating Engineers
- Old Republic Insurance Co.
- Oracle Corp.
- Thermo Fisher Scientific Inc.
- Verita Global LLC
- Houlihan Lokey Inc.
- American Federation of Labor & Congress of Industrial Organizations
- Jefferies Financial Group Inc.
- Teva Pharmaceutical Industries Ltd.
Government Agencies
- Pension Benefit Guaranty Corp.
- Missouri Department of Revenue
- U.S. District Court for the District of Columbia
- Tennessee Attorney General's Office
- Pala Band of Mission Indians
- Seldovia Village Tribe
- Nez Perce Tribe
- Town of Ramapo, New York
- Jamestown S'Klallam Tribe
- St. Regis Mohawk Tribe
- State of Indiana
- City of Bayonne, New Jersey
- Washington State Department of Revenue
- Colorado Attorney General's Office
- Port Gamble S'Klallam Tribe
- Borough of Paramus, New Jersey
- State of Nevada
- Northwestern Band of the Shoshone Nation
- Town of Babylon, New York
- Town of Brookhaven, New York
- New York Department of Financial Services
- Town of Hempstead, New York
- Commonwealth of Massachusetts
- Hopi Tribe
- Suquamish Tribe
- Ohio Attorney General's Office
Sectors & Industries:
-
September 30, 2020
Purdue Pharma Gets OK For Payments, Opioid Suit Shield
A New York bankruptcy judge on Wednesday gave Purdue Pharma another five months free from opioid suits and permission to make $26 million in employee retention payments after being told claim distribution mediation between the drugmaker and its creditors is bearing fruit.
-
September 22, 2020
Trustee Bristles At New $45M Purdue Bid For Ch. 11 Bonuses
The Office of the United States Trustee objected Tuesday to a proposed $45 million Chapter 11 bonus plan from bankrupt painkiller maker Purdue Pharma, saying the company has already been approved to pay $38 million in retention and incentive bonuses to employees and the new plan doesn't contain meaningful benchmarks.
-
September 21, 2020
Sens. Call Purdue CEO Bonus An 'Affront' To Opioid Victims
A handful of U.S. senators urged a New York bankruptcy judge Monday to reject a compensation proposal that could see Purdue Pharma CEO Craig Landau pocket a bonus of up to $3.5 million, calling the possibility an "affront" to victims of the opioid crisis.
-
September 17, 2020
Purdue Wants Opioid Suit Ch. 11 Shield Extended To March
Purdue Pharma LP is asking a New York bankruptcy court to extend the injunction blocking thousands of suits against it over its role in the opioid crisis until March, saying that allowing the stay to expire in October would scuttle the progress it's made in its reorganization efforts.
-
August 26, 2020
NAACP To Get Its Say On Purdue Ch. 11 Opioid Settlement
Purdue Pharma told a New York bankruptcy judge Wednesday that the NAACP will get its seat at the table in the mediation to determine how the assets of the bankrupt drugmaker will be distributed to victims of the opioid crisis.
-
August 18, 2020
Purdue And Sacklers Caused $2.16T In Damage, NY Says
New York and 48 other states on Monday told a bankruptcy court that Purdue Pharma LP and its former owners the Sackler family have caused almost $2.16 trillion in damage to the U.S. after two decades of pushing opioids.
-
August 07, 2020
NAACP Wants Seat At Table In Purdue Bankruptcy Case
The NAACP on Friday asked a New York bankruptcy judge for a seat at the table in the Purdue Pharma Chapter 11, saying it needs to ensure a fair share of the proceeds of the case's opioid settlement goes to communities of color.
-
July 23, 2020
Judge To Wait On Claim Talks Result For Purdue Class Call
A New York bankruptcy judge Thursday agreed to adjourn a request to allow five new classes of alleged opioid victims to file claims in Purdue Pharma's Chapter 11 until after claim mediation ends, saying an agreement there would mean he wouldn't have to rule.
-
July 16, 2020
Purdue Asks Court To Say No To New Classes In Ch. 11 Case
Purdue Pharma asked a New York bankruptcy judge Thursday to reject requests to allow five claims by classes of alleged opioid victims in its Chapter 11 case, saying adding new classes would be an unnecessary, last-minute complication.
-
June 23, 2020
Purdue Gets OK For $6.5M Investment In Overdose Drug
A New York bankruptcy judge gave Purdue Pharma permission Tuesday to invest $6.5 million in a company working on an over-the-counter opioid-overdose drug, saying that keeping the development effort going was an appropriate use of the opioid-maker's money.